首站-论文投稿智能助手
典型文献
Novel cellular therapies for hepatobiliary malignancies
文献摘要:
Background:The mortalities of hepatobiliary malignancies are high.With the failure of conventional chemotherapy and unsatisfactory outcome of molecular targeted drugs,immune-based therapy has be-come a new focus of research in hepatobiliary cancers treatment.Data sources:We performed a PubMed search with relevant articles published up to May 2022 and the following keywords:cellular immunotherapy,hepatobiliary cancer,antigen receptor T cell therapy,and receptor-engineered T cell.Information of clinical trials was obtained from therapies for hepatobiliary malignancies are at early stage of development.The current re-view showed that cellular therapies are safe and feasible in patients.These findings provide an important platform for future lager scale clinical trials on immunotherapy in patients with hepatobiliary malignan-cies.Conclusions:With the continuous advances of cellular immunotherapy,the combination of cellular im-munotherapy with surgery,chemotherapy and radiotherapy will be new therapeutic strategies for pa-tients with hepatobiliary cancer .
文献关键词:
作者姓名:
Jing-Nan Xue;Yan-Yu Wang;Yun-Chao Wang;Nan Zhang;Long-Hao Zhang;Zheng-Hui Lu;Li-Jin Zhao;Hai-Tao Zhao
作者机构:
Department of Liver Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100730,China;Department of Hepatobiliary and Pancreatic Surgery,Affiliated Hospital of Zunyi Medical University,Zunyi 563000,China;Hepatobiliary and Pancreatic Surgery,Shenzhen Qianhai Shekou Free Trade Zone Hospital,Shenzhen 518000,China
引用格式:
[1]Jing-Nan Xue;Yan-Yu Wang;Yun-Chao Wang;Nan Zhang;Long-Hao Zhang;Zheng-Hui Lu;Li-Jin Zhao;Hai-Tao Zhao-.Novel cellular therapies for hepatobiliary malignancies)[J].国际肝胆胰疾病杂志(英文版),2022(05):450-454
A类:
malignan
B类:
Novel,cellular,therapies,hepatobiliary,malignancies,Background,mortalities,are,high,With,failure,conventional,chemotherapy,unsatisfactory,outcome,molecular,targeted,drugs,immune,has,be,new,focus,research,cancers,treatment,Data,sources,We,performed,relevant,articles,published,up,May,following,keywords,immunotherapy,antigen,receptor,engineered,Information,clinical,trials,was,obtained,from,early,stage,development,current,view,showed,that,safe,feasible,patients,These,findings,provide,important,platform,future,lager,scale,Conclusions,continuous,advances,combination,surgery,radiotherapy,will,therapeutic,strategies
AB值:
0.526048
相似文献
Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer
Xinyi Zhou;Qian Xiao;Dongliang Fu;Haochen Zhang;Yang Tang;Jinjie He;Yeting Hu;Xiangxing Kong;Fei Teng;Xiangrui Liu;Ying Yuan;Kefeng Ding-Department of Colorectal Surgery and Oncology,Key Laboratory of Cancer Prevention and Intervention,Ministry of Education,the Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310009,China;Department of Medical Oncology,Key Laboratory of Cancer Prevention and Intervention,Ministry of Education,the Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310009,China;Hangzhou Oncocare Co Ltd,Hangzhou 310009,China;Department of Pharmacology,Zhejiang University School of Medicine,Hangzhou 310058,China;Cancer Center,Zhejiang University,Hangzhou 310009,China
The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma
Jia Lu;Ting Li;Zhichao Liao;Hui Yu;Yongtian Zhao;Haixiao Wu;Zhiwu Ren;Jun Zhao;Ruwei Xing;Sheng Teng;Yun Yang;Xiangchun Li;Kexin Chen;Jonathan Trent;Jilong Yang-Department of Bone and Soft Tissue Tumor,2Department of Infection Management,3Key Laboratory of Molecular Cancer Epidemiology,Tianjin Medical University Cancer Institute&Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China;YuceBio Technology Co.,Ltd.,Shenzhen 518172,China;Department of Epidemiology and Biostatistics,Tianjin Medical University Cancer Institute&Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China;Sarcoma Multidisciplinary Program,Sylvester Comprehensive Cancer Center,The University of Miami,Miami,FL 33136,USA
Reporting and methodological quality of meta-analyses of acupuncture for patients with migraine:A methodological investigation with evidence map
Ting-ting Lu;Cun-cun Lubc;Mei-xuan Li;Li-xin Ke;Hui Cai;Ke-hu Yang-Institution of Clinical Research and Evidence-Based Medicine,Gansu Provincial Hospital,Lanzhou 730000,Gansu Province,China;Evidence-Based Medicine Center,School of Basic Medical Sciences,Lanzhou University,Lanzhou 730000,Gansu Province,China;Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China;Key Laboratory of Evidence-Based Medicine and Knowledge Translation of Gansu Province,Lanzhou 730000,Gansu Province,China;Hepatobiliary and Pancreatic Center,the First Affiliated Hospital,Sun Yat-sen University,Guangzhou 510080,Guangdong Province,China;General Surgery Clinical Medical Center,Gansu Provincial Hospital,Lanzhou 730000,Gansu Province,China
Moxibustion for COVID-19: a systematic scoping review
Meng Xia;Bo Pang;Shaowei Yi;Xinjue Shan;Shizhe Deng;Yinan Qin;Tao Jiang;Hai Lu-Alberta College of Acupuncture&Traditional Chinese Medicine,Alberta,Canada;Evidence-based Medicine Center,TianjinUniversity of Traditional Chinese Medicine,Tianjin,China;School of Acupuncture-moxibustion and Tuina,Tianjin University of Traditional Chinese Medicine,Tianjin,China;School of Traditional ChineseMedicine,Tianjin University of Traditional Chinese Medicine,Tianjin,China;Department of Acupuncture and Moxibustion,First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin,China;National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion,Tianjin,China;School of Acupuncture-moxibustion and Tuina,Shaanxi University of Chinese Medicine,Xianyang,China;Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School,Nanjing,China
Therapeutic potential of colchicine in cardiovascular medicine:a pharmacological review
Fan-shun Zhang;Qing-ze He;Chengxue Helena Qin;Peter J.Little;Jian-ping Weng;Suo-wen Xu-Institute of Endocrine and Metabolic Diseases,The First Affiliated Hospital of USTC,Division of Life Science and Medicine,University of Science and Technology of China,Hefei 230001,China;Faculty of Pharmacy and Pharmaceutical Sciences,Monash Institute of Pharmaceutical Sciences,Monash University(Parkville Campus),381 Royal Parade,Parkville 3052 VIC,Australia;Sunshine Coast Health Institute,University of the Sunshine Coast,Birtinya 4575 QLD,Australia;School of Pharmacy,The University of Queensland,Woolloongabba 4102 QLD,Australia;Biomedical Sciences and Health Laboratory of Anhui Province,University of Science&Technology of China,Hefei 230027,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。